Ahmedabad: Intas Pharmaceutical today said it has launched `Mabtas` a new low cost drug for treating cancer in India.
"Mabtas, is a biosimilar version of Rituximab, a type of protein therapy for treatment of cancer. It makes treatment cheaper by between Rs 20,000 to 50,000 as compared to existing similar drugs in the market," Intas Biopharmaceuticals Vice President R&D Dr Himanshu Gadgil said.
The company is third one in India to launch such a biosimilar after pharmaceutical companies like Roche and Dr Reddy. The new drug competes with biosimilars like Restova and Reditux, already available in market for last many years.
"It is third such biosimilar now available in Indian market. It costs around Rs 41,800 per cycle, for treating cancer patients, who have to be administered dosages in six cycles," he said.
Biosimilars, are biologic medical products whose active drug substance is made by a living organism or derived from a living organism by means of recombinant DNA or controlled gene expression methods.
"The multi centric trials conducted on 101 patients has proven its efficacy as well as safety.
The drug can be used for treating Non-Hodgkin`s Lymphoma (blood cancer) and Rheumatoid Arthritis," Gadgil said.
"The drug has potential to cure lymphoma even in very advanced stage...The success rate of this therapy is high," a company doctor claimed.
Intas, recently received European Union-Good Manufacturing Practice (EU-GMP) certification, for manufacturing recombinant biologics.
According to industry estimates, around 50,000 new patients of Lymphoma (cancer) get added in India every year. The market size of such cancer treating drugs is pegged around Rs 110-120 crore.
PTI
By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.
Cookies Setting
By clicking “Accept All Cookies”, you agree to the storing of cookies on your device and the processing of information obtained via those cookies (including about your preferences, device and online activity) by us and our commercial partners to enhance site navigation, personalise ads, analyze site usage, and assist in our marketing efforts. More information can be found in our Cookies and Privacy Policy. You can amend your cookie settings to reject non-essential cookies by clicking Cookie Settings below.
Manage Consent Preferences
Strictly Necessary Cookies
These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will not then work or you may not be able to login.
Functional Cookies
These cookies enable the website to provide enhanced functionality and personalisation. They may be set by us or by third party providers whose services we have added to our pages. If you do not allow these cookies then some or all of these services may not function properly.
Targeting Cookies
These cookies may be set through our site by our advertising partners. They may be used by those companies to build a profile of your interests and show you relevant adverts on other sites. They are also used to limit the number of times you see an advert as well as help measure the effectiveness of an advertising campaign. They do not store directly personal information, but are based on uniquely identifying your browser and internet device. If you do not allow these cookies, you will experience less targeted advertising.
Performance Cookies
These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. All information these cookies collect is aggregated and therefore anonymous. If you do not allow these cookies we may not know when you have visited our site, and may not be able to monitor its performance.